• To conduct a literature review covering both published and grey literature (on agency websites) on CED, and identify examples of CED activities worldwide;
• Based on the finding of the literature review, develop a framework for CED policy implementation in Canada.
Method
• Examples of CED programs from 1998-2009 were based on a published systematic review by Carlson et al. 1 • CED is a subset of performance-based risk-sharing arrangements where price, level or nature of reimbursement are generally linked to effectiveness using clinical or intermediate endpoints ultimately related to patient quality or quantity of life ( Figure 1 ).
• Ovid Medline, Embase, Health Technology Assessment, and NHS Economic Evaluation Database were searched from 2010 to November 8th, 2012, for articles with the following keywords: "coverage with evidence development", "access with evidence development", "conditional coverage", "access with evidence", "coverage with evidence", "conditionally funded field evaluations", "only in research", "only with research", "coverage with study participation", and "field evaluations".
• Grey literature was searched on Google, and websites of government ministries of health, cancer agencies, national health technology assessment agencies and reimbursement authorities in several countries (including Canada, United Kingdom (UK), United States (US), Australia, Italy, France, Netherlands, and Sweden).
• Countries differ in the type of scheme employed:  US and UK have used primarily OIR, whereas Sweden has used only OWR.
• Most CED programs aimed to address more than one type of uncertainty including:  Clinical benefit, value for money, adoption and diffusion, and affordability.
• CED programs were generally managed by independent, government-funded non-profit research organizations (e.g. National Institute of Health in the US), or university-based academic centers, or professional societies (e.g. American College of Cardiology).
• Only 38% (N=28) of the identified drug and non-drug CED schemes reported study outcomes and funding decisions.  61% (N=17) was successfully funded; 7% (N=2) was partially funded (one in a subgroup, and one with price reduction); 7% (N=2) evaluated multiple technologies and only the cost-effective strategy was funded;  18% (N=5) was not funded; 7% (N=2) could not reach a final funding decision.
Results
• In the literature, CED is distinguished into two subtypes: 2  "OIR": the technology is provided only within a research program, undertaken to address the decision uncertainty, and for a patient to have access to the technology, participation in that research program is mandatory.  "OWR": the technology is reimbursed for qualifying patients under the condition that further research is undertaken to generate additional evidence.
• A total of 74 CED schemes were identified in 9 countries:  35 of these evaluated drugs and 39 evaluated non-drugs ( Figure 2) ;  A summary of the 35 drug CED programs is presented in Table 1 ;  Oncology was the most common therapeutic area for CED (Figure 3 ).
Conclusion
• Although a large number of CED programs were identified, only limited information of final decisions was publically available.
• CED is a promising mechanism to reduce uncertainty and aid patient access, but on many accounts it has proven challenging to implement. 
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